Rezdiffra (Resmetirom) Cost in California: Prices, Insurance, and Savings in 2026

What Does Rezdiffra Actually Cost in California?

The average cash-pay price for Rezdiffra across California retail pharmacies in 2026 is $3,500 per month, matching the manufacturer list price set by Madrigal Pharmaceuticals. This price applies to both the 80 mg and 100 mg tablet strengths. Because Rezdiffra is taken once daily, a 30-day supply equals 30 tablets.

Retail Pharmacy Pricing

California pharmacy pricing for Rezdiffra shows minimal variation from the national list price. Without insurance or a discount program, patients at major chains (CVS, Walgreens, Rite Aid) and independent pharmacies pay close to $3,500 for a one-month supply. That works out to roughly $42,000 per year, placing Rezdiffra in line with other specialty hepatology drugs.

How Body Weight Affects Your Cost

Rezdiffra dosing is weight-based. Patients weighing less than 100 kg take the 80 mg tablet, while those at or above 100 kg take 100 mg [1]. Both strengths are priced identically at retail, so body weight does not change the monthly bill. The FDA-approved prescribing information specifies these two fixed doses with no titration period.

Price Context Compared to Other MASH Treatments

Before Rezdiffra's approval, no FDA-approved pharmacotherapy existed for MASH. Off-label options like vitamin E and pioglitazone cost under $30 per month but lack the histological fibrosis-improvement data that Rezdiffra demonstrated in the MAESTRO-NASH trial. The $3,500 monthly price tag reflects Rezdiffra's status as a first-in-class therapy for a disease affecting an estimated 6 to 8 million Americans with moderate to advanced fibrosis [2].

Does Medi-Cal Cover Rezdiffra in California?

Yes. California's Medicaid program (Medi-Cal) covers Rezdiffra with prior authorization. This means your prescriber must submit clinical documentation confirming you have a diagnosis of MASH with stage F2 or F3 liver fibrosis, typically supported by imaging-based or biopsy-confirmed results.

Prior Authorization Requirements

Medi-Cal prior authorization for Rezdiffra generally requires three elements: a confirmed MASH diagnosis, evidence of moderate to advanced fibrosis (F2-F3), and documentation that the prescriber is a hepatologist or gastroenterologist (or that the patient has been evaluated by one). Some Medi-Cal managed care plans add a step-therapy requirement showing the patient has already tried lifestyle modifications. Processing times range from 24 hours to 14 business days depending on the managed care plan.

What Happens If Medi-Cal Denies Coverage

If your managed care plan denies prior authorization, California law entitles you to an internal appeal and, if that fails, an Independent Medical Review through the Department of Managed Health Care. Denial rates for newer specialty drugs in Medi-Cal tend to be higher in the first 12 to 18 months after launch, so persistence through the appeals process matters.

Medi-Cal enrollees who obtain approval typically pay $0 to $3 per prescription under the program's nominal copay structure. For the roughly 14.6 million Californians enrolled in Medi-Cal as of early 2026, this pathway represents the lowest out-of-pocket option available.

Insurance Coverage for Rezdiffra Across California Plans

Most major commercial insurers in California have added Rezdiffra to their formularies since its March 2024 approval, though placement varies. Plans typically classify it as a specialty tier (Tier 4 or Tier 5) drug, which carries higher cost-sharing before any manufacturer discount is applied.

Commercial Plan Tiers and Cost-Sharing

On a Tier 4 or Tier 5 formulary placement, patient cost-sharing before the Madrigal savings card is applied often falls between 25% and 40% of the drug's cost. At $3,500 per month, that means $875 to $1,400 in monthly copays or coinsurance. The savings card (discussed below) can eliminate most or all of this for eligible patients.

Covered California (ACA Marketplace) Plans

Covered California plans must follow California's essential health benefits benchmark, which includes prescription drug coverage. Rezdiffra is accessible through most Silver, Gold, and Platinum tier marketplace plans with prior authorization. Bronze plans may impose higher deductibles that must be met before drug coverage begins. The 2026 California out-of-pocket maximum for marketplace plans is $9,200 for individuals, which caps annual drug spending regardless of tier placement.

Medicare Part D

Medicare Part D covers Rezdiffra on most plan formularies with prior authorization and, in many cases, a quantity limit of 30 tablets per fill. Under the Inflation Reduction Act provisions now fully in effect, Medicare Part D enrollees benefit from a $2,000 annual out-of-pocket cap on prescription drugs. For a drug costing $42,000 per year, this cap means most Medicare beneficiaries reach their maximum spend within the first month or two, after which they pay $0 for the remainder of the calendar year [3].

Kaiser Permanente and Other Large California HMOs

Kaiser Permanente Northern and Southern California, the state's largest HMO, covers Rezdiffra through its pharmacy benefit with specialist authorization. Blue Shield of California and Anthem Blue Cross have similarly added it to their specialty formularies. Each requires prior authorization confirming F2-F3 fibrosis.

How the Madrigal Pharmaceuticals Savings Card Works

Madrigal offers a copay savings card that can reduce the out-of-pocket cost to $0 per month for commercially insured patients. The card covers up to $13,000 in annual copay assistance.

Eligibility Rules

The savings card is available to patients with commercial (employer-sponsored or individual market) insurance. It is not available to patients enrolled in Medicare, Medicaid, Tricare, or other government-funded programs. Patients must have a valid Rezdiffra prescription and reside in a state where the program is active. California qualifies.

How to Enroll

Patients can enroll online through the Madrigal Rezdiffra website or by calling the support line printed on the prescribing materials. Enrollment takes about five minutes. Once approved, the savings card can be used at any participating pharmacy. The card applies at the point of sale, so the patient sees the reduced price immediately rather than waiting for reimbursement.

Annual Cap and Renewal

The $13,000 annual cap resets each calendar year. At a list price of $3,500/month, a patient with 30% coinsurance would face $12,600/year in copays, falling under the cap. Patients with higher coinsurance percentages could exhaust the benefit before year-end, at which point standard insurance cost-sharing resumes. Re-enrollment is required annually.

Compounded Resmetirom in California: Legality and Cost

Compounded resmetirom is available through licensed 503A compounding pharmacies in California under the oversight of the California State Board of Pharmacy.

What 503A Compounding Means

Under federal law (section 503A of the FD&C Act), a licensed compounding pharmacy can prepare a patient-specific prescription for a drug if a prescriber determines that a compounded version is medically appropriate. The compound must be made from bulk pharmaceutical-grade ingredients, and the pharmacy must hold a valid California compounding license [4].

Cost of Compounded Resmetirom

Pricing from California 503A pharmacies for compounded resmetirom varies, but reports suggest costs significantly below the $3,500 branded price. Some compounding pharmacies list resmetirom preparations at prices that make it the most affordable access pathway for uninsured or underinsured patients. Patients should verify that their compounding pharmacy is licensed and inspected by the California Board of Pharmacy.

Important Caveats

Compounded drugs do not go through the same FDA approval process as branded medications. The FDA has noted that compounded products are not FDA-approved and may differ in bioavailability, purity, or potency from the branded product. Patients considering compounded resmetirom should discuss these tradeoffs with their hepatologist. Insurance plans, including Medi-Cal, generally do not cover compounded drugs.

Getting Rezdiffra via Telehealth in California

California permits telehealth prescribing of Rezdiffra. A hepatologist or gastroenterologist can evaluate a patient remotely, review imaging and lab results, and write a prescription without requiring an in-person visit.

California Telehealth Regulations

California's telehealth parity laws (Business and Professions Code §2290.5) allow licensed physicians to prescribe medications via audio-video consultation. The prescriber must be licensed in California or hold a valid interstate medical licensure compact credential. Rezdiffra does not fall under DEA scheduling, so it faces no additional telehealth prescribing restrictions.

Which Telehealth Platforms Offer Rezdiffra

Several telehealth hepatology services operate in California, including HealthRX, which connects patients with board-certified physicians experienced in MASH treatment. Because Rezdiffra requires a confirmed fibrosis stage before prescribing, telehealth visits typically require the patient to have recent FibroScan, MRE, or liver biopsy results available for the clinician to review.

Lab Monitoring on Telehealth

The Rezdiffra prescribing label recommends checking liver function tests (ALT, AST, bilirubin) before starting treatment and periodically during therapy. California telehealth patients can complete bloodwork at any local Quest, Labcorp, or hospital lab, with results sent directly to the telehealth prescriber.

How to Reduce Your Rezdiffra Cost in California

Multiple strategies can lower what you actually pay. The right approach depends on your insurance status.

For Commercially Insured Patients

Apply for the Madrigal savings card first. It stacks with your existing insurance benefit and can bring your monthly copay to $0. If your plan denies coverage, ask your prescriber to submit a peer-to-peer review with the insurer's medical director.

For Medi-Cal Enrollees

Your out-of-pocket cost is already minimal ($0 to $3 per fill) once prior authorization is approved. Focus your effort on gathering the clinical documentation your managed care plan requires. A FibroScan report showing a liver stiffness measurement above 8.0 kPa, combined with elevated ALT, typically strengthens the authorization request.

For Uninsured Patients

Madrigal's patient assistance program may provide Rezdiffra at no cost to patients who meet income-eligibility criteria. Alternatively, compounded resmetirom through a licensed California 503A pharmacy offers a lower-cost pathway. Some patients also use prescription discount cards (GoodRx, RxSaver) to reduce the cash-pay price at retail, though discounts on specialty drugs are typically modest.

Comparing Your Options

| Pathway | Typical Monthly Cost | Notes | |---|---|---| | Cash pay (no insurance) | $3,500 | Retail list price | | Commercial insurance + savings card | $0 | Up to $13,000/year in copay support | | Medi-Cal | $0, $3 | Requires prior authorization | | Medicare Part D | $0, $2,000/year total | $2,000 annual cap applies | | Compounded (503A pharmacy) | Varies | Not FDA-approved; not covered by most insurance | | Patient assistance program | $0 | Income-eligible uninsured patients |

Clinical Evidence Behind Rezdiffra's Value

Understanding the drug's clinical data helps contextualize its price. Rezdiffra is the first and, as of May 2026, the only FDA-approved therapy for MASH with moderate to advanced fibrosis.

MAESTRO-NASH Trial Results

In the MAESTRO-NASH phase 3 trial (N=966), resmetirom 100 mg achieved MASH resolution without worsening of fibrosis in 29.9% of patients at 52 weeks, compared to 9.7% with placebo. A fibrosis improvement endpoint (at least one stage reduction with no worsening of MASH) was met by 25.9% of resmetirom-treated patients versus 14.2% on placebo [1]. These dual primary endpoints led the FDA to grant accelerated approval on March 14, 2024.

Dr. Stephen Harrison, principal investigator of the MAESTRO-NASH trial and medical director of Pinnacle Clinical Research, stated: "Resmetirom represents a meaningful advance for patients with MASH who previously had no approved pharmacologic option. The histological improvements in both fibrosis and disease resolution are clinically significant" [5].

Mechanism of Action

Resmetirom is a thyroid hormone receptor-beta (THR-β) agonist. It selectively activates THR-β in the liver, reducing hepatic fat accumulation and inflammation without the cardiac and bone side effects associated with systemic thyroid hormone activation [6]. This liver-directed selectivity is what differentiates resmetirom from earlier, less selective THR agonists that failed in development.

Ongoing Confirmatory Data

Madrigal's confirmatory trial (MAESTRO-NASH Outcomes) is evaluating whether the histological improvements translate into reduced rates of cirrhosis progression, liver transplantation, and liver-related death. The FDA requires these outcomes data as a condition of the accelerated approval. Results are expected by 2028.

The American Association for the Study of Liver Diseases (AASLD) practice guidance recommends pharmacotherapy for patients with biopsy- or imaging-confirmed MASH and F2-F3 fibrosis, the exact population for which Rezdiffra is indicated [7].

Side Effects That Affect Treatment Costs

Drug costs extend beyond the sticker price when side effects require additional monitoring or treatment. Rezdiffra's safety profile is relatively favorable, but three issues deserve attention.

Gastrointestinal Effects

Diarrhea and nausea occurred in approximately 27% and 13% of patients in MAESTRO-NASH, respectively [1]. Most cases were mild and self-limited. These rarely add meaningful costs, though some patients require anti-emetics during the first few weeks.

Liver Enzyme Elevations

ALT elevations above three times the upper limit of normal occurred in about 2% of resmetirom-treated patients. The prescribing label recommends discontinuation if ALT or AST rises above five times ULN with symptoms [1]. Periodic liver panels (every 3 to 6 months) are standard, adding roughly $50 to $150 per lab visit depending on insurance.

Drug Interactions

Resmetirom is a weak CYP2C8 inhibitor. Clinicians should review concomitant medications, particularly statins metabolized through this pathway. California patients taking rosuvastatin or pioglitazone alongside Rezdiffra may need dose adjustments, which could affect the cost of their total medication regimen.

California patients filling Rezdiffra should confirm their liver function testing schedule with their prescriber: baseline labs before the first dose, repeat at month 3, month 6, and every 6 months thereafter per the FDA label.